Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07593079 | Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer | not yet recruiting | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815197 | Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer(PERSEUS) | not yet recruiting | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 11, 2026 |
| clinicaltrials |
| NCT07815665 | A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma(HARMONi-GU1) | recruiting | Phase 2 / Phase 3 | 800 | Summit TherapeuticsINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | not yet recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02101775 | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 3 | Sep 10, 2026 | clinicaltrials |
| NCT02397083 | Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer(LEVER) | active not recruiting | Phase 2 | 102 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03315754 | Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. | completed | Phase 2 | 50 | Steba Biotech S.A.OTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04683653 | Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | suspended | Phase 1 / Phase 2 | 100 | University of ChicagoOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04865887 | Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | recruiting | Phase 2 | 35 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04931342 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors(BOUQUET) | active not recruiting | Phase 2 | 176 | Hoffmann-La RocheINDUSTRY | 13 | Sep 10, 2026 | clinicaltrials |
| NCT05762536 | Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC(DAROTAXEL) | recruiting | Phase 2 | 245 | Erasmus Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05766371 | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | recruiting | Phase 2 | 48 | University of California, San FranciscoOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05877820 | A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC | completed | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06100705 | Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC | recruiting | Phase 2 | 26 | Yale UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06480565 | A Phase 1/2 Trial of ADI-270 in ccRCC | active not recruiting | Phase 1 / Phase 2 | 60 | Adicet TherapeuticsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer(ADE-LACC) | not yet recruiting | Phase 2 | 35 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT00365157 | Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction | active not recruiting | Phase 1 / Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 349 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02595892 | Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02675829 | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | completed | Phase 2 | 131 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03317392 | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | active not recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03367741 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN) | recruiting | Phase 2 / Phase 3 | 138 | ARCAGY/ GINECO GROUPOTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT04592237 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05287945 | Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 75 | Oncorena ABINDUSTRY | 5 | Sep 9, 2026 | clinicaltrials |
| NCT07226713 | Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors(POSTPONE) | recruiting | Phase 2 | 32 | Medical College of WisconsinOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07256223 | A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07529717 | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer(CRIUS-1) | recruiting | Phase 1 / Phase 2 | 42 | AstraZenecaINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07576335 | Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy(ROBOPREP) | recruiting | Phase 2 | 64 | Surgical Outcomes Research Centre (SOuRCe)NETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03976843 | Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | active not recruiting | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY) | active not recruiting | Phase 2 | 47 | Rana McKay, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07189793 | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study(OHAI-NMIBC-01) | not yet recruiting | Phase 2 | 106 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07224009 | Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) | recruiting | Phase 2 | 60 | University of ArkansasOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807293 | Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE(SALVAGE) | not yet recruiting | Phase 2 | 62 | University of British ColumbiaOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT04597359 | To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Sep 4, 2026 | clinicaltrials |
| NCT06384222 | Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone | active not recruiting | Phase 2 | 32 | Ivan de Kouchkovsky, MDOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06794229 | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis(EXPLORE-RCC) | recruiting | Phase 2 | 69 | Qian QinOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07188896 | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | recruiting | Phase 2 | 120 | Brian RiniOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07567846 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 260 | Genentech, Inc.INDUSTRY | 3 | Sep 4, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT01410942 | Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy | active not recruiting | Phase 2 | 175 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03173924 | 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04633252 | A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05411081 | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | active not recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05521997 | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06096870 | Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy | recruiting | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | Phase 2 | 85 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07005154 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | recruiting | Phase 2 | 218 | Astellas Pharma Global Development, Inc.INDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07285694 | AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | active not recruiting | Phase 1 / Phase 2 | 190 | Arsenal Biosciences, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials